Korean drugmakers urged to develop biosimilars

Domestic pharmaceutical firms will need to focus on development of promising biosimilars or similar biologics, considering the lack of money and resources to develop new drugs, according to market experts.

Unlike the more common "small-molecule" drugs, biologics generally exhibit high molecular complexity, and may be quite sensitive to manufacturing process changes. The follow-on manufacture...